Clinical Trials Logo
  1. Home
  2. CMV Infection
  3. NCT05315882

Cytomegalovirus Infection After HSCT and PT-CY as GVHD Prophylaxis >> GVHD PROPHYLAXIS ERA — CY-CMV-2020  

CMV Infection Clinical Trial

Official title:
Cytomegalovirus Infection, Indirect Effects and Mortality in Hematopoietic Stem Cell Transplantation With Cyclophosphamide Post-transplant

Clinical Trial Summary

Multicentre, observational, retrospective study to analyze the differences in CMVi pattern and recurrences between two groups of allogeneic HSCT patients (haplo vs no haplo HSCT), with intervention both postransplant cyclophosphamide as GvHD prophylaxis, using a database with information from historical clinic data.

Clinical Trial Description

The overall aim of the study is to to analize CMVi after PTCy for GVHD prophylaxis, with a detailed description of CMVi and recurrences, direct and indirect consequences, in a HSCT population comparing two cohorts: haploidentical HSCT vs no haploidentical HSCT ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05315882
Study type Observational
Source Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y Salud
Contact
Status Completed
Phase
Start date February 14, 2020
Completion date December 17, 2020
View Details
See also
  Status Clinical Trial Phase
Completed NCT03067155 - CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation. Phase 2
Completed NCT02324244 - CMV Intensive Care Units N/A
Enrolling by invitation NCT06263218 - Real-world CMV Outcomes Among Kidney Transplant Recipients in Brazil
Recruiting NCT04934527 - Association of T Gamma Delta-CD16+ Cells and Anti-CMV Immunoglobulins in the Prevention of CMV Infection Phase 2
Not yet recruiting NCT06075927 - Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT Phase 1/Phase 2
Not yet recruiting NCT06341686 - Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection Phase 3
Recruiting NCT02136797 - Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation Phase 2
Terminated NCT02843880 - Prediction of Cytomegalovirus (CMV) Reactivation in Intensive Care Unit (ICU) by Immunological Study N/A
Recruiting NCT04278547 - Multicenter Clinical Trial to Evaluate the Efficacy of a Preventive Strategy Against CMV Infection in Heart Transplant Patients, Based on the Specific T Cells Response Phase 4
Recruiting NCT06021210 - Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS Phase 2
Active, not recruiting NCT01633476 - CMV Modulation of the Immune System in ANCA-associated Vasculitis Phase 2
Suspended NCT02988258 - Study of Adoptive Immunotherapy With Donor-derived CMV-specific T Cells for Recipients of Allo-HSCT Phase 1
Recruiting NCT04017962 - A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection Phase 2
Recruiting NCT03159364 - Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections Phase 1/Phase 2
Recruiting NCT05089838 - CMV-TCR-T Cells for Refractory CMV Infection After HSCT Phase 1
Enrolling by invitation NCT05656599 - Immune Reconstitution to CMV After HSCT: Impact of Clinical Factors and Therapy Strategies
Completed NCT02985775 - Preemptive Therapy With CMV-specific T Cells Infusion to Prevent Refractory CMV Infection Post Transplantation Phase 1/Phase 2
Recruiting NCT02083731 - MSC for Treatment of CMV Infection Phase 2
Recruiting NCT02779439 - Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation Phase 1
Recruiting NCT03798301 - Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells Phase 1